Chongqing Pharscin Pharmaceutical (SHE:002907) obtained the approval of China's National Medical Products Administration become the marketing authorization holder of the Jian'er Xiaoshi oral liquid, according to a Shenzhen bourse filing on Saturday.
The Chinese pharmaceutical company's shares rose over 2% at the close of Monday's trade.
The drug is used to improve digestion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments